Literature DB >> 24907387

Food and Drug Administration responds to pressure for expanded drug access.

Vicki Brower.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 24907387     DOI: 10.1093/jnci/dju171

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

1.  The ethics and regulatory landscape of including vulnerable populations in pragmatic clinical trials.

Authors:  Mary Jane Welch; Rachel Lally; Jennifer E Miller; Stephanie Pittman; Lynda Brodsky; Arthur L Caplan; Gina Uhlenbrauck; Darcy M Louzao; James H Fischer; Benjamin Wilfond
Journal:  Clin Trials       Date:  2015-09-15       Impact factor: 2.486

2.  Right-to-try laws and individual patient "compassionate use" of experimental oncology medications: A call for improved provider-patient communication.

Authors:  Michael Hoerger
Journal:  Death Stud       Date:  2015-08-27

3.  Recommendations to Facilitate Expanded Access to Investigational Therapies for Seriously Ill Patients.

Authors:  Rebecca N Jerome; Terri L Edwards; Haley C Boswell; Gordon R Bernard; Paul A Harris; Jill M Pulley
Journal:  Acad Med       Date:  2016-03       Impact factor: 6.893

4.  Going "social" to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access.

Authors:  Tim K Mackey; Virginia J Schoenfeld
Journal:  BMC Med       Date:  2016-02-02       Impact factor: 8.775

Review 5.  Compassionate drug use: Current status in India.

Authors:  Yashashri C Shetty; Smita Brahma; P S Manjesh
Journal:  Perspect Clin Res       Date:  2019-04-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.